{"product_id":"amgn-bcg-matrix","title":"(AMGN) Amgen Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Amgen Inc. BCG Matrix shows how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs, helping with strategy, portfolio review, and investment decisions. The page already includes a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepatha, 2015 launch, PCSK9 leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepatha, launched in 2015, is one of Amgen Inc.'s fastest-growing cardiovascular brands. In 2024, it topped $2 billion in sales, helped by broader LDL-C use and a leading PCSK9 position, so it combines strong growth with clear share gains. That profile fits a Star in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVENITY, 2019 launch, osteoporosis growth brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVENITY, launched in 2019, targets a global osteoporosis market that affects over 200 million people worldwide, with risk rising as populations age. In 2025, its continued uptake and reimbursement gains keep it in a growth phase for Amgen and UCB, and that rising demand fits the Star profile: high growth, strong adoption, and a large addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMGEVITA, adalimumab biosimilar, Europe scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMGEVITA fits a Star profile in Europe: adalimumab is still a huge biologics market, and Humira generated about $14.4 billion in 2024 sales. Amgen's biosimilar scale helps it win tenders and expand access across countries. That mix of large volume and strong growth supports a Star-like position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMVASI, bevacizumab biosimilar, oncology volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMVASI, the bevacizumab biosimilar, keeps Amgen in a large oncology lane where switching from originators still drives volume. Bevacizumab has been used since 2004, and MVASI entered the U.S. in 2019, so it benefits from a deep, established demand base.\u003c\/p\u003e\n\u003cp\u003eOncology biologics remain a high-volume category, and biosimilar adoption keeps widening as payers push lower-cost options. That makes MVASI a clear Star: it sits in a growing market and gives Amgen meaningful share exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBevacizumab market is mature, still large\u003c\/li\u003e\n\u003cli\u003eMVASI supports oncology biosimilar growth\u003c\/li\u003e\n\u003cli\u003eSwitching pressure favors biosimilar volume\u003c\/li\u003e\n\u003cli\u003eAmgen gains scale in a key category\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKANJINTI, trastuzumab biosimilar, HER2 franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKANJINTI fits Amgen Inc. as a Star: it serves the HER2 oncology franchise, where trastuzumab biosimilars keep taking share even as the core market is mature. In 2025, that mix still matters because biosimilar uptake expands access and keeps pressure on legacy branded pricing.\u003c\/p\u003e\n\u003cp\u003eAmgen Inc. benefits from a broad trastuzumab class with multiple biosimilar options, so KANJINTI is not a dead-growth asset. It is a growth-plus-share play, with value tied to ongoing conversion in breast and gastric cancer treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHER2 is mature, but biosimilar share keeps rising.\u003c\/li\u003e\n\u003cli\u003eKANJINTI supports Amgen Inc. oncology scale.\u003c\/li\u003e\n\u003cli\u003eBest fit: Star in the BCG Matrix.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s Star Assets Are Winning in Fast-Growing Biologic Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen Inc.'s Stars are Repatha and its biosimilars KANJINTI, MVASI, and AMGEVITA. Repatha passed $2 billion in 2024 sales, while AMGEVITA, MVASI, and KANJINTI keep gaining share in large, still-growing biologic markets. These assets match the BCG Star test: high growth plus rising adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024\/2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepatha\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$2B sales\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMGEVITA\u003c\/td\u003e\n\u003ctd\u003eHumira market $14.4B\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMVASI\u003c\/td\u003e\n\u003ctd\u003eOncology biosimilar volume\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKANJINTI\u003c\/td\u003e\n\u003ctd\u003eOngoing HER2 share gains\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAmgen’s BCG Matrix maps its drug portfolio to spot stars, cash cows, question marks, and divestible laggards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAmgen Inc. BCG Matrix: one-page quadrant view to quickly spot growth winners and cash cows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Amgen’s key assumptions, making due diligence faster and decisions easier to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnbrel, 1998 launch, long-running TNF franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnbrel, launched in 1998, remains one of Amgen Inc.’s longest-running blockbusters and a classic Cash Cow. In 2024, Enbrel generated about $3.3 billion in sales, even as the TNF market stayed mature and grew slowly. That mix of high cash flow and limited growth fits the BCG Cash Cow profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProlia, 2010 launch, osteoporosis standard\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProlia, launched in 2010, remains Amgen Inc.’s osteoporosis standard and a true Cash Cow. In the latest reported year, it generated about $4.5B in sales, showing deep brand trust and steady demand. The bone-health market is mature, so growth is slower, but high margins and repeat use keep franchise economics strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXgeva, 2010 launch, bone-metastasis therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Amgen Inc.'s 2025 annual report, Xgeva stayed a mature oncology support brand, used to prevent skeletal events in patients with bone metastases. The market is low-growth, but Xgeva still generated about $2.0 billion in 2025 sales, showing durable demand. That steady cash flow and high clinical utility keep Xgeva in Cash Cow territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOtezla, 2014 launch, immune-dermatology brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOtezla is a mature cash cow for Amgen: the immune-dermatology brand has a large installed base in psoriasis and psoriatic arthritis, and Amgen reported about $2.0 billion in Otezla sales in 2024. The market is crowded, but demand stays steady, so it keeps throwing off dependable cash instead of chasing growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2014 launch; durable brand equity\u003c\/li\u003e\n\u003cli\u003ePsoriasis and PsA remain core uses\u003c\/li\u003e\n\u003cli\u003e~$2.0B 2024 sales for Amgen\u003c\/li\u003e\n\u003cli\u003eMature market, steady cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn BCG terms, Otezla fits the Cash Cow bucket because it still monetizes a proven franchise with limited need for heavy reinvestment. Its role is to fund Amgen's newer growth assets while defending share in a mature, competitive category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNplate, 2008 launch, ITP franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNplate, launched in 2008, is an established immune thrombocytopenia (ITP) therapy in a specialized hematology niche. Its long market history and recurring treatment need support steady demand, while growth is likely modest because the franchise is mature, not new.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2008 launch; 17-year franchise by 2025\u003c\/li\u003e\n\u003cli\u003eSpecialized ITP market with recurring use\u003c\/li\u003e\n\u003cli\u003eStable demand supports Cash Cow status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s Cash Cows Keep the Engine Running\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen Inc.'s Cash Cows are mature brands with steady demand and strong cash flow: Enbrel ($3.3B in 2024), Prolia ($4.5B in 2024), Xgeva ($2.0B in 2025), Otezla ($2.0B in 2024), and Nplate. They sit in slow-growing markets, but their long product lives and repeat use keep margins high and reinvestment needs low. These brands help fund Amgen Inc.'s newer growth assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eLatest sales\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnbrel\u003c\/td\u003e\n\u003ctd\u003e$3.3B\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProlia\u003c\/td\u003e\n\u003ctd\u003e$4.5B\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXgeva\u003c\/td\u003e\n\u003ctd\u003e$2.0B\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOtezla\u003c\/td\u003e\n\u003ctd\u003e$2.0B\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAmgen Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Amgen Inc. BCG Matrix preview you see is the exact same document you’ll receive after purchase. No demo pages, no hidden edits—just the complete, ready-to-use report. Once purchased, you get the full file for immediate download and practical use. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeupogen, 1991 launch, legacy G-CSF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeupogen, launched in 1991, is a legacy G-CSF supportive-care drug for Amgen Inc. It fits the Dogs quadrant: low growth and low strategic share as biosimilars keep pressuring the class. Amgen Inc. has said biosimilar erosion has reduced Neupogen’s role, with the product now a mature, shrinking cash item rather than a growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeulasta, 2002 launch, maturing pegfilgrastim\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeulasta, launched in 2002, is still recognized, but its growth has faded as biosimilar competition has eroded the franchise over time. Amgen reported Neulasta sales of about $0.6 billion in 2024, far below its peak, so it now looks more like a low-growth, shrinking cash generator than a growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpogen, 1989 launch, dialysis ESA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpogen, launched in 1989, is a mature dialysis ESA with limited growth left. The market has been pressured for years by biosimilars and generics, so upside is capped and pricing power is weak. In Amgen Inc.’s 2025 mix, this is a classic Dogs asset: low-growth, legacy, and cash-generative but not a growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSensipar\/Mimpara, mature CKD mineral-bone brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSensipar\/Mimpara is a mature CKD mineral-bone brand with long-running generic and competitive pressure, so Amgen has little room left to expand it. In BCG terms, that means low growth and weak strategic priority, which is classic Dog territory. Capital is better directed to higher-growth assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, mature category\u003c\/li\u003e\n\u003cli\u003eHeavy generic competition\u003c\/li\u003e\n\u003cli\u003eLimited expansion potential\u003c\/li\u003e\n\u003cli\u003eFits Dog in BCG Matrix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVectibix, 2006 launch, niche oncology share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVectibix, launched in 2006, remains a niche EGFR therapy for KRAS wild-type metastatic colorectal cancer. Its market is crowded, and growth is far slower than newer oncology launches. That mix of low share and modest growth fits the Dog quadrant in Amgen Inc.'s BCG view.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized colorectal cancer use\u003c\/li\u003e\n\u003cli\u003eCompetitive, mature market\u003c\/li\u003e\n\u003cli\u003eLow share, limited growth\u003c\/li\u003e\n\u003cli\u003eDog quadrant fit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s Dog Brands Face Biosimilar Pressure and Limited Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen Inc.’s Dogs are mature, shrinking cash flows: Neupogen, Neulasta, Epogen, Sensipar, and Vectibix all face biosimilar or generic pressure with little growth left. Neulasta sales were about $0.6 billion in 2024, and the rest sit in low-share, low-growth niches. These brands fit the Dog quadrant, so capital is better kept in higher-growth assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeulasta\u003c\/td\u003e\n\u003ctd\u003e$0.6B\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpogen\u003c\/td\u003e\n\u003ctd\u003eMature\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVectibix\u003c\/td\u003e\n\u003ctd\u003eNiche\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMariTide (AMG 133), phase 2 obesity asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMariTide (AMG 133) is still a phase 2 obesity asset, so Amgen Inc. has no sales from it yet. The prize is huge: obesity drugs from Eli Lilly and Novo Nordisk already drive tens of billions of dollars in annual sales, and the category is among the fastest-growing in pharma. If MariTide shows strong weight-loss data and wins adoption, it could move from Question Mark to Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlpasiran (AMG 890), phase 3 Lp(a) cardiovascular asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlpasiran (AMG 890) is a phase 3 lipoprotein(a), or Lp(a), cardiovascular asset in a market that is still forming. Lp(a) is an inherited risk factor linked to a higher chance of heart attack and stroke, and olpasiran has no sales share yet.\u003c\/p\u003e\n\u003cp\u003eAmgen Inc.'s 2025-2026 value here is option value, not revenue: the drug is still in late-stage testing, so current financial contribution is $0. If phase 3 data support outcomes benefit, it could open a large new franchise in a disease area with few approved options.\u003c\/p\u003e\n\u003cp\u003eThat makes olpasiran a clear Question Mark in the BCG Matrix: high potential, but unproven. Its next readout will decide whether it stays a pipeline bet or turns into a future growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMDELLTRA, 2024 launch, small-cell lung cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMDELLTRA, launched in 2024 and FDA approved in May 2024 for relapsed extensive-stage small-cell lung cancer, fits a Question Mark in Amgen Inc.'s BCG Matrix. Small-cell lung cancer is about 15% of lung cancers, so the addressable pool is meaningful, but this is still a new launch and share is limited. Growth upside is real if Amgen keeps building uptake, but it is not yet a cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTavneos, 2021 launch, ANCA vasculitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTavneos, launched in 2021 for ANCA-associated vasculitis, targets a rare disease with roughly 40 to 60 cases per million people each year, so its patient pool is small but expandable. Adoption is still building, and Amgen has not turned it into a mature cash engine yet, which fits a Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2021 launch in a rare autoimmune niche\u003c\/li\u003e\n\u003cli\u003eSmall current brand, still growing uptake\u003c\/li\u003e\n\u003cli\u003eExpansion potential, but not a cash cow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAMG 193, phase 1 PRMT5 inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMG 193 is a phase 1 PRMT5 inhibitor for precision oncology, so it fits Amgen Inc. as a Question Mark: high upside if data hold, but no commercial share yet. Early assets like this can target a large biomarker-defined pool, yet value still depends on proof of response, safety, and dose. In BCG terms, it is promise plus uncertainty.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 1 only, no sales yet\u003c\/li\u003e\n\u003cli\u003eHigh-risk, high-upside oncology bet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s Pipeline Bets: Big Upside, No 2025-2026 Sales Base Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen Inc.'s Question Marks are pipeline or early-launch bets with big upside but no durable 2025-2026 revenue base yet. MariTide and olpasiran are still in late-stage testing, while IMDELLTRA, Tavneos, and AMG 193 are early growth assets with limited share, so each needs strong data or uptake to become a Star.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025-2026 status\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMariTide\u003c\/td\u003e\n\u003ctd\u003ePhase 2, $0 sales\u003c\/td\u003e\n\u003ctd\u003eHigh-upside Question Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlpasiran\u003c\/td\u003e\n\u003ctd\u003ePhase 3, $0 sales\u003c\/td\u003e\n\u003ctd\u003eUnproven Question Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMDELLTRA\u003c\/td\u003e\n\u003ctd\u003e2024 launch, early uptake\u003c\/td\u003e\n\u003ctd\u003eGrowth bet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTavneos\u003c\/td\u003e\n\u003ctd\u003e2021 launch, niche market\u003c\/td\u003e\n\u003ctd\u003eBuilding Question Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMG 193\u003c\/td\u003e\n\u003ctd\u003ePhase 1, no sales\u003c\/td\u003e\n\u003ctd\u003eSpeculative Question Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191755972873,"sku":"amgn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/amgn-bcg-matrix.webp?v=1783678427","url":"https:\/\/dcfanalyst.com\/products\/amgn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}